Multiple Sclerosis Center, Swedish Neuroscience Institute — Seattle, Washington

Multiple Sclerosis Center, Swedish Neuroscience Institute is a clinical research site located in Seattle, Washington, United States 98122.

Crixeo Health Trust Score: 60/100 (FAIR). This profile has not yet been claimed by the site owner.

Multiple Sclerosis Center, Swedish Neuroscience Institute has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis.

Sponsors: National Institute of Allergy and Infectious Diseases (NIAID), Providence Health & Services.

Sponsor Feasibility Report

Trust Score: 60/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Multiple Sclerosis Center, Swedish Neuroscience Institute?

Multiple Sclerosis Center, Swedish Neuroscience Institute has a Crixeo Trust Score of 60/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Multiple Sclerosis Center, Swedish Neuroscience Institute conducted?

Multiple Sclerosis Center, Swedish Neuroscience Institute has 2 clinical trials on record, with 1 currently active. Their work covers Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis.

Is Multiple Sclerosis Center, Swedish Neuroscience Institute accredited by Crixeo Health?

Multiple Sclerosis Center, Swedish Neuroscience Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Multiple Sclerosis Center, Swedish Neuroscience Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.